drugset / Trial / NCT07698613

EGFR Targeted Photoimmunotherapy With ASP-1929 for Locally Advanced Pancreatic Cancer

NCT07698613

NaSingle-groupOpen-labelTreatment

Summary

This is an open label phase II study to determine the safety and preliminary efficacy of photoimmunotherapy (PIT) for patients with locally advanced and borderline resectable pancreatic cancer.

Timeline

Start
2026-09
Primary completion
2029-03
Completion
2033-09

Drugs

EvaluationDrugModalityDoseRoute
Subject CETUXIMAB SAROTALOCAN Other / unclassified Intravenous

Indications